Raymond James Evaluation !!! VALUATION from earlier this year.
We value CRDL as the sum of two parts: Part 1: Discounted cash flow analysis (DCF) of Canadian medical cannabis revenues using an 8% discount rate and terminal rate of 2%; and Part 2: Risk- adjusted net present value analysis (rNPV) of itsacute myocarditis clinical asset. Summing these parts, we calculate a present value per share of $5.22, which we round to $5.00, and ascribe CRDL an Outperform rating. See Valuation section for more detail.
GO CRDL!